Clinical Trial Update: A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 dose-escalation trial of AEB1102 in patients with advanced solid tumors completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancers

Drugs mentioned

• AEB1102

Snippet

Sponsor: Aeglea Biotherapeutics | Conditions: Advanced Cancers | Phase 1, Phase 2 | Status: COMPLETED